Amarin develops and markets Vascepa (icosapent ethyl), a prescription omega-3 therapy used to reduce elevated triglycerides and cardiovascular risk in specific patient groups. The product is sold directly in the United States and through partners across multiple international markets. It serves healthcare providers treating patients with lipid disorders and persistent cardiovascular risk.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 42 | — | -15.7 | — |
| Q2 2025 | 72.7 | — | -14.1 | — |
| Q3 2025 | 49.7 | — | -7.7 | — |
| Q4 2025 | 49.2 | — | -1.2 | — |
| Q1 2026 | 45.1 | 7.4% | -10.5 | — |
| Q2 2026 | 42.2 | -42% | -7.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: RideNow Group, Inc. (RDNW), enCore Energy Corp. (EU), Sutro Biopharma, Inc. (STRO), Magnitude International Ltd (MAGH), CAMP4 THERAPEUTICS CORPORATION (CAMP), Utah Medical Products, Inc. (UTMD)